Pulmonary hypertension in adults completing tuberculosis treatment

Main Article Content

B W Allwood
S Manie
M Stolbrink
L Hunter
S Mathee
G Meintjes
S L Amosun
A Pecoraro
G Walzl
E Irusen


Background. Pulmonary hypertension (PH) after tuberculosis (TB) is typically not included among the chronic lung diseases causing PH (group 3 PH), with few data available to support the inclusion.

Objectives. To determine the prevalence of PH in an adult population completing TB treatment.

Methods. This single-centre, cross-sectional study only included patients with their first documented episode of TB, and who were in the second half of treatment or had recently completed treatment. PH was assessed using transthoracic echocardiography. Questionnaires were also completed and spirometry and a 6-minute walk test were performed.

Results. One hundred patients were enrolled, with a mean age of 37.1 years, of whom 58% were male and 46% HIV positive. The median time since initiation of TB treatment was 22 weeks. The mean (standard deviation) measured right ventricular systolic pressure (RVSP) was 23.6 (6.24) mmHg. One participant had PH (defined as RVSP ≥40 mmHg; 95% confidence interval (CI) 0.0 - 3.0) and a further 3 had possible PH (RVSP ≥35 and <40 mmHg), with a combined PH prevalence of 4% (95% CI 0.2 - 7.8). Airflow obstruction on spirometry was found in 13.3% of 98 patients, while 25.5% had a reduced forced vital capacity. There was no association between RVSP or PH/possible PH and sex, age, HIV status, systemic hypertension, spirometry measurements or 6-minute walking distance. Smoking status was associated with RVSP, but not with the presence of PH/possible PH.

Conclusion. There was a significant prevalence of PH in this preliminary study of predominantly young patients completing treatment for a first episode of TB. Larger and more detailed studies are warranted.

Article Details

How to Cite
Pulmonary hypertension in adults completing tuberculosis treatment. (2023). African Journal of Thoracic and Critical Care Medicine, 29(3), 122-126. https://doi.org/10.7196/AJTCCM.2023.v29i3.676
Original Research: Articles

How to Cite

Pulmonary hypertension in adults completing tuberculosis treatment. (2023). African Journal of Thoracic and Critical Care Medicine, 29(3), 122-126. https://doi.org/10.7196/AJTCCM.2023.v29i3.676


Hoeper MM, Humbert M, Souza R, et al. A global view of pulmonary hypertension. Lancet Respir Med 2016;4(4):306-322. https://doi.org/10.1016/S2213-2600(15)00543-3 2. Nathan SD, Barbera JA, Gaine SP, et al. Pulmonary hypertension in chronic lung disease and hypoxia. Eur Respir J 2019;53(1):1801914. https://doi.


Enea I, Ghio S, Bongarzoni A, et al. [Echocardiographic alterations suggestive of pulmonary hypertension in the Italian ultrasonography laboratories. Epidemiological data from the INCIPIT study (INCidence of Pulmonary Hypertension in Italian ulTrasonography laboratories)]. G Ital Cardiol (Rome) 2010;11(5):402-407.

Humbert M, Kovacs G, Hoeper MM, et al. 2022 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J 2022;43(38):3618-3731. https://doi.org/10.1093/eurheartj/ehac237

Dodd PJ, Yuen CM, Jayasooriya SM, van der Zalm MM, Seddon JA. Quantifying the global number of tuberculosis survivors: A modelling study. Lancet Infect Dis 2021;21(7):984-992. https://doi.org/10.1016/S1473-3099(20)30919-1

Allwood BW, van der Zalm MM, Amaral AFS, et al. Post-tuberculosis lung health: Perspectives from the First International Symposium. Int J Tuberc Lung Dis 2020;24(8):820-828. https://doi.org/10.5588/ijtld.20.0067

Samuelsson S. Chronic cor pulmonale in pulmonary tuberculosis. Acta Med Scand 1952;142(5):315-324. https://doi.org/10.1111/j.0954-6820.1952.tb13871.x

Walzer I, Frost T. Cor pulmonale: A consideration of clinical and autopsy findings. Dis Chest 1954;26(2):192-198.

Chen Y, Liu C, Lu W, et al. Clinical characteristics and risk factors of pulmonary hypertension associated with chronic respiratory diseases: A retrospective study. J Thorac Dis 2016;8(3):350-358. https://doi.org/10.21037/jtd.2016.02.58

Allwood BW, Maarman GJ, Kyriakakis CG, Doubell AF. Post-pulmonary tuberculosis complications in South Africa and a potential link with pulmonary hypertension: Premise for clinical and scientific investigations. S Afr Med J 2018;108(7):529. https:// doi.org/10.7196/SAMJ.2018.v108i7.13359

Marjani M, Baghaei P, Malekmohammad M, et al. Effect of pulmonary hypertension on outcome of pulmonary tuberculosis. Braz J Infect Dis 2014;18(5):487-490. https:// doi.org/10.1016/j.bjid.2014.02.006

Akkara AS, Shah AD, Adalja M, Akkara AG, Rathi A, Shah DN. Pulmonary tuberculosis: The day after. Int J Tuberc Lung Dis 2013;17(6):810-813. https://doi. org/10.5588/ijtld.12.0317

Vyslouzil Z, Polak J, Widimsky J, Sukova M. Pathogenesis of pulmonary hypertension in tuberculosis. Czech Med 1980;3(2):123-131.

Graham BL, Steenbruggen I, Miller MR, et al. Standardisation of spirometry 2019 update. An official American Thoracic Society and European Respiratory Society technical statement. Am J Respir Crit Care Med 2019;200(8):e70-e88. https://doi. org/10.1164/rccm.201908-1590ST

Zaidi A, Knight DS, Augustine DX, et al.; British Society for Echocardiography. Echocardiographic assessment of the right heart in adults: A practical guideline from the British Society of Echocardiography. Echo Res Pract 2020;7(1):G19-G41. https:// doi.org/10.1530/ERP-19-0051

Huluka DK, Mekonnen D, Abebe S, et al. Prevalence and risk factors of pulmonary hypertension among adult patients with HIV infection in Ethiopia. Pulm Circ 2020;10(4):2045894020971518. https://doi.org/10.1177/2045894020971518

Allwood BW, Maasdorp E, Kim GJ, et al. Transition from restrictive to obstructive lung function impairment during treatment and follow-up of active tuberculosis. Int J Chron Obstruct Pulmon Dis 2020;15:1039-1047. https://doi.org/10.2147/COPD.S219731

MeghjiJ,LesoskyM,JoekesE,etal.Patientoutcomesassociatedwithpost-tuberculosis lung damage in Malawi: A prospective cohort study. Thorax 2020;75(3):269-278. https://doi.org/10.1136/thoraxjnl-2019-213808

Kalla IS, Miri A, Seedat F. Occult pulmonary arterial hypertension in patients with previous pulmonary tuberculosis. Afr J Thorac Crit Care Med 2020;26(4):133-137. https://doi.org/10.7196/AJTCCM.2020.v26i4.110

Keusch S, Hildenbrand FF, Bollmann T, et al. Tobacco smoke exposure in pulmonary arterial and thromboembolic pulmonary hypertension. Respiration 2014;88(1):38-45. https://doi.org/10.1159/000359972

Huang SK. Knocking out smoking and pulmonary hypertension with a K. Am J Respir Crit Care Med 2021;203(10):1216-1218. https://doi.org/10.1164/rccm.202011-4121ED 22. Allwood BW, Byrne A, Meghji J, Rachow A, van der Zalm MM, Schoch OD. Post- tuberculosis lung disease: Clinical review of an under-recognised global challenge.

Respiration 2021;100(8):751-763. https://doi.org/10.1159/000512531

Ahmed AEH, Ibrahim AS, Elshafie SM. Pulmonary hypertension in patients with treated pulmonary tuberculosis: Analysis of 14 consecutive cases. Clin Med Insights

Circ Respir Pulm Med 2011;5:1-5. https://doi.org/10.4137/CCRPM.S6437

RichJD,ShahSJ,SwamyRS,KampA,RichS.InaccuracyofDopplerechocardiographic estimates of pulmonary artery pressures in patients with pulmonary hypertension: Implications for clinical practice. Chest 2011;139(5):988-993. https://doi.org/10.1378/


Similar Articles

You may also start an advanced similarity search for this article.

Most read articles by the same author(s)